MergerLinks Header Logo

Announced

Completed

Viatris completed the acquisition of a 5.1% stake in Syngene from Biocon for $153m.

Synopsis

Viatris, a global pharmaceutical company, completed the acquisition of a 5.1% stake in Syngene, an innovation-led contract research, development and manufacturing organization, from Biocon, an Indian biopharmaceutical company, for $153m.

Principals

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

All rights reserved. Copyright © 2025 Datasite